The short answer
Papers are frequently corrected after publication, and the correction is a separate indexed record. Both the August 2026 aleniglipron Phase 2b and the survodutide comparison trial carry corrections, and citing either without checking is how errors persist.
Key facts
- Aleniglipron trial
- PMID 42249138, Nat Med 2026
- Its correction
- PMID 42343118, Nat Med 2026
- Survodutide trial
- PMID 38095657, Diabetologia 2024
- Its correction
- PMID 38349400, Diabetologia 2024
- Correction type
- Separate indexed record
- Usual cause
- Production or data presentation errors
What a correction is
A separate published item recording that something in the original was wrong. Publisher corrections typically address production errors. A mislabelled figure, a transposed value, an author affiliation. Author corrections address errors in the work itself. Both are part of the permanent record and both are indexed independently.
Why they are easy to miss
Because they are separate records. Searching for a trial returns the trial; the correction is a different entry that appears only if you look for it or if the database surfaces it. Anyone citing from a reference list, a press summary or a secondary source will never encounter it.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Two live examples in current incretin literature
The aleniglipron Phase 2b appeared in Nature Medicine in August 2026 and a publisher correction was indexed the same month. The survodutide dose-response trial appeared in Diabetologia in 2024 and a correction followed. These are two of the most-cited recent papers in oral and dual-agonist obesity pharmacology respectively.
What a correction usually does not mean
That the findings were wrong. Most corrections are minor and leave conclusions intact, treating the existence of one as evidence against a paper is as unreflective as ignoring it. The point is to know what the current version of the record says, not to score a point.
Why this site checks
Because it has already found seventeen citations here that resolved to entirely unrelated papers, two PubChem records that were different drugs, and three wrong trial registration numbers. The habits that catch those are the same habits that catch a correction: resolve every identifier, read what actually comes back, and check whether anything followed it.
How to check quickly
A PubMed record links its corrections directly. Searching the paper's title will usually return both the original and any correction adjacent to each other. It takes seconds, and it is the difference between citing the record and citing a memory of it.
Frequently asked questions
Does a correction mean the study was wrong?
Usually not. Most are minor production or presentation errors that leave the conclusions intact.
Why are corrections so easy to miss?
They are separate indexed records. Searching for a trial returns the trial, not the correction.
Which current obesity papers carry corrections?
The August 2026 aleniglipron Phase 2b in Nature Medicine, and the survodutide dose-response trial in Diabetologia.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedRosenstock J et al., aleniglipron phase 2b. Nat Med 2026 (PMID 42249138)pubmed.ncbi.nlm.nih.gov
- PubMedPublisher Correction: aleniglipron phase 2b. Nat Med 2026 (PMID 42343118)pubmed.ncbi.nlm.nih.gov
- PubMedBlüher M et al., survodutide dose-response. Diabetologia 2024 (PMID 38095657)pubmed.ncbi.nlm.nih.gov
- PubMedCorrection to Blüher M et al. Diabetologia 2024 (PMID 38349400)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Amycretin's Move to Phase 3Novo Nordisk advanced amycretin to Phase 3 in 2026 on the strength of a Lancet phase 1b/2a. What that early trial was, and what it was not.
- REDEFINE 4: The Head-to-Head Novo Nordisk Lost809 adults, 84 weeks, open-label. CagriSema reached 23.0% against tirzepatide's 25.5% and did not meet its non-inferiority endpoint.
- CagriSema After REDEFINE 4A failed head-to-head does not block an approval. What regulators actually assess, and what changed for CagriSema in February 2026.
- Searching a Trial Name Often Finds the Wrong TrialREDEFINE 4 has no acronym in ClinicalTrials.gov - searching for it returns REDEFINE 1, 2 and 3. How to find and check a registration properly.
- Accelerated Approval Is a Conditional StatementApproval on a surrogate endpoint, with confirmatory evidence required afterwards. Why that is a genuinely different decision from a standard approval.